1. Signaling Pathways
  2. Cell Cycle/DNA Damage
  3. DNA/RNA Synthesis

DNA/RNA Synthesis

RNA synthesis, which is also called DNA transcription, is a highly selective process. Transcription by RNA polymerase II extends beyond RNA synthesis, towards a more active role in mRNA maturation, surveillance and export to the cytoplasm.

Single-strand breaks are repaired by DNA ligase using the complementary strand of the double helix as a template, with DNA ligase creating the final phosphodiester bond to fully repair the DNA.DNA ligases discriminate against substrates containing RNA strands or mismatched base pairs at positions near the ends of the nickedDNA. Bleomycin (BLM) exerts its genotoxicity by generating free radicals, whichattack C-4′ in the deoxyribose backbone of DNA, leading to opening of the ribose ring and strand breakage; it is an S-independentradiomimetic agent that causes double-strand breaks in DNA.

First strand cDNA is synthesized using random hexamer primers and M-MuLV Reverse Transcriptase (RNase H). Second strand cDNA synthesis is subsequently performed using DNA Polymerase I and RNase H. The remaining overhangs are converted into blunt ends using exonuclease/polymerase activity. After adenylation of the 3′ ends of DNA fragments, NEBNext Adaptor with hairpin loop structure is ligated to prepare the samples for hybridization. Cell cycle and DNA replication are the top two pathways regulated by BET bromodomain inhibition. Cycloheximide blocks the translation of mRNA to protein.

DNA/RNA Synthesis Related Products (62):

Cat. No. Product Name Effect Purity
  • HY-12320
    Cycloheximide Inhibitor 99.45%
    Cycloheximide (Naramycin A) is an eukaryote protein synthesis inhibitor, with IC50s of 532.5 nM and 2880 nM for protein synthesis and RNA synthesis in vivo, respectively.
  • HY-17559
    Actinomycin D Inhibitor 99.89%
    Actinomycin D inhibits DNA repair with an IC50 of 0.42 μM.
  • HY-13316
    Mitomycin C Inhibitor 98.89%
    Mitomycin C is an antitumor drug and antibiotic that shows extraordinary ability to inhibit DNA synthesis. Mitomycin C is a DNA cross-linking agent, which induces DNA damaging.
  • HY-17026
    Gemcitabine Inhibitor 99.92%
    Gemcitabine (NSC 613327;LY188011) is a DNA synthesis inhibitor which inhibits the growth of BxPC-3, Mia Paca-2, PANC-1, PL-45 and AsPC-1 cells with IC50s of 37.6, 42.9, 92.7, 89.3 and 131.4 nM, respectively.
  • HY-13753
    Streptozocin Inhibitor 99.58%
    Streptozocin is a potent DNA-methylating agent, with IC50s of 11.7, 904 and 1024 μg/mL in HL60, K562 and C1498 cells respectively.
  • HY-14776
    Quarfloxin Inhibitor
    Quarfloxin (CX 3543), a fluoroquinolone derivative with antineoplastic activity, targets and inhibits RNA pol I activity, with IC50 values in the nanomolar range in neuroblastoma cells. Quarfloxin disrupts the interaction between the nucleolin protein and a G-quadruplex DNA structure in the ribosomal DNA (rDNA) template.
  • HY-N1584A
    Halofuginone hydrobromide Inhibitor 99.94%
    Halofuginone hydrobromide (RU-19110 hydrobromide) is a less-toxic form of Febrifugine, which is isolated from the plant Dichroa febrifuga. Halofuginone inhibits prolyl-tRNA synthetase in an ATP-dependent manner with a Ki of 18.3 nM. Halofuginone attenuates osteoarthritis (OA) by inhibition of TGF-β activity.
  • HY-111806
    3,7,4'-Trihydroxyflavone
    3,7,4'-Trihydroxyflavone, isolated from Rhus javanica var. roxburghiana, is a flavonoid with DNA strand-scission activity.
  • HY-19610
    alpha-Amanitin Inhibitor 99.79%
    alpha-Amanitin is the principal toxin of several deadly poisonous mushrooms, exerting its toxic function by inhibiting RNA-polymerase II.
  • HY-17565
    Bleomycin sulfate Inhibitor >98.0%
    Bleomycin sulfate is a DNA synthesis inhibitor with potent antitumor activity.
  • HY-17393
    Carboplatin Inhibitor 99.93%
    Carboplatin (NSC 241240) is a DNA synthesis inhibitor which binds to DNA, inhibits replication and transcription and induces cell death. Carboplatin (NSC 241240) is a derivative of CDDP and a potent anti-cancer agent.
  • HY-B0003
    Gemcitabine Hydrochloride Inhibitor 99.93%
    Gemcitabine hydrochloride is a DNA synthesis inhibitor with IC50s of 37.6, 42.9, 92.7, 89.3 and 131.4 nM in BxPC-3, Mia Paca-2, PANC-1, PL-45 and AsPC-1 cells, respectively.
  • HY-18982
    Anisomycin Inhibitor 98.20%
    Anisomycin is a potent protein synthesis inhibitor which interferes with protein and DNA synthesis by inhibiting peptidyl transferase or the 80S ribosome system.
  • HY-12742
    SCR7 Inhibitor 99.75%
    SCR7 is a DNA Ligase IV inhibitor with anticancer activity and is also a CRISPR HDR enhancer which increases the efficiency of Cas9-mediated HDR.
  • HY-13323
    CX-5461 Inhibitor 98.47%
    CX-5461 is a potent and oral rRNA synthesis inhibitor. It inhibits RNA polymerase I-driven transcription of rRNA with IC50s of 142, 113, and 54 nM in HCT-116, A375, and MIA PaCa-2 cells, respectively.
  • HY-B0016
    Capecitabine Inhibitor 99.97%
    Capecitabine is an oral prodrug that is converted to its active metabolite, 5-FU, by thymidine phosphorylase.
  • HY-19620
    Branaplam Agonist 99.67%
    Branaplam (LMI070) is a highly potent, selective and orally active small molecule SMN2 splicing modulator.
  • HY-B0313
    Hydroxyurea Inhibitor >98.0%
    Hydroxyurea is a cell apoptosis inducer that inhibitDNA synthesis through inhibition of ribonucleotide reductase.
  • HY-19931
    COH29 Inhibitor 98.04%
    COH29 is a potent ribonucleotide reductase (RNR) inhibitor with anticancer activity. COH29 inhibits α and β subunit of RNR with IC50s of 16 μM.
  • HY-N1584
    Halofuginone Inhibitor 98.32%
    Halofuginone (RU-19110) is a less-toxic form of Febrifugine, which is isolated from the plant Dichroa febrifuga. Halofuginone inhibits prolyl-tRNA synthetase in an ATP-dependent manner with a Ki of 18.3 nM. Halofuginone attenuates osteoarthritis (OA) by inhibition of TGF-β activity.
Isoform Specific Products

Your Search Returned No Results.

Sorry. There is currently no product that acts on isoform together.

Please try each isoform separately.